Clinical Trial Update: Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating oral arsenic in combination with all-trans retinoic acid (ATRA) for newly diagnosed acute promyelocytic leukemia; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• All-trans Retinoic Acid (all-trans retinoic acid)
• Arsenic trioxide (oral) (arsenic trioxide)

Snippet

Sponsor: Instituto do Cancer do Estado de São Paulo | Conditions: Acute Promyelocytic Leukemia (APL) | Phase 2 | Status: RECRUITING